Newson AJ, Tiller J, Keogh LA, Otlowski M, Lacaze P. Genetics and Insurance in Australia: Concerns around a Self-Regulated Industry. Public Health Genomics. 2017. [Epub ahead of print]
Archibald AD, Smith MJ, Burgess T, Scarf KL, Elliott J, Hunt CE, et al. Reproductive genetic carrier screening for cystic fibrosis, fragile X syndrome, and spinal muscular atrophy in Australia: outcomes of 12,000 tests. Genetics in Medicine. 2017. [Epub ahead of print]
Stark Z, Dashnow H, Lunke S, Tan TY, Yeung A, Sadedin S, et al. A clinically driven variant prioritization framework outperforms purely computational approaches for the diagnostic analysis of singleton WES data. European Journal of Human Genetics. 2017. 25 (11) : 1268-1272.
Walsh M, Bell KM, Chong B, Creed E, Brett GR, Pope K, et al. Diagnostic and cost utility of whole exome sequencing in peripheral neuropathy. Annals of clinical and translational neurology. 2017. 4 (5) : 318—325.
Bauer D.C, Zadoorian A, Wilson L.O, Melbourne Genomics Health Alliance, Thorne N.P. Evaluation of computational programs to predict HLA genotypes from genomic sequencing data. Briefings in Bioinformatics. 2016. [Epub ahead of print]
Doble B, Schofield D, Roscioli T, Mattick J. The promise of personalised medicine. The Lancet. 2016. 387 (10017) : 433—34.
Mallawaarachchi A.C, Hort Y, Cowley M.J, McCabe M.J, Minoche A, Dinger M.E, et al. Whole-genome sequencing overcomes pseudogene homology to diagnose autosomal dominant polycystic kidney disease. European Journal of Human Genetics. 2016. 24 (11) : 1584—1590.
Mallett, A., Fowles, L.F., McGaughran, J., Healy, H., & Patel, C. (2016). A multidisciplinary renal genetics clinic improves patient diagnosis. Med J Aust, 204(2), 58-59.
Ross DM, Altamura HK, Hahn CN, Nicola M, Yeoman A L, Holloway MR, et al. Delayed diagnosis leading to accelerated-phase chronic eosinophilic leukemia due to a cytogenetically cryptic, imatinib-responsive TNIP1-PDFGRB fusion gene. Leukemia. 2016. 30 (6) : 1402—5.
Lewinsohn M, Brown AL, Weinel LM, Phung C, Rafidi G. Lee MK, et al. Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies. Blood. 2016. 127 (8) : 1017—23.